head and neck squamous cell carcinoma (Cancer)
Information
- Disease name
- head and neck squamous cell carcinoma
- Disease ID
- DOID:5520
- Description
- "A head and neck carcinoma that has_material_basis_in squamous cells that line the moist, mucosal surfaces inside the head and neck." [url:http\://en.wikipedia.org/wiki/Head_and_neck_cancer#Squamous_cell_carcinoma, url:http\://www.cancer.gov/cancertopics/factsheet/Sites-Types/head-and-neck, url:http\://www.cancer.gov/dictionary?CdrID=597171]
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT05156177 | Active, not recruiting | Correlation of Fecal Microbiome and Its Metabolites With Outcome of Radiotherapy in Head and Neck Carcinoma | December 1, 2021 | December 2024 | |
| NCT04490564 | Active, not recruiting | Validation of Molecular Diagnostic Assays to Detect Cancer Biomarkers in Blood and Primary Tumor in HNSCC/NSCLC/Melanoma | June 25, 2019 | June 25, 2023 | |
| NCT02567422 | Active, not recruiting | Phase 1 | Testing the Addition of M6620 (VX-970, Berzosertib) to Usual Chemotherapy and Radiation for Head and Neck Cancer | April 17, 2017 | April 23, 2025 |
| NCT04452032 | Active, not recruiting | Phase 2 | Prospective Pilot Study Evaluating Dental Side Effects of Radiotherapy on Subjects Treated for Head and Neck Cancer | November 17, 2020 | May 16, 2027 |
| NCT04414540 | Active, not recruiting | Phase 2 | Combining Pembrolizumab and Metformin in Metastatic Head and Neck Cancer Patients | August 31, 2020 | July 2025 |
| NCT05145907 | Active, not recruiting | Phase 2 | Study to Evaluate Safety and Efficacy of TJ107 Combine With PD-1 in Patients With Solid Tumors | December 22, 2021 | December 31, 2024 |
| NCT04357873 | Active, not recruiting | Phase 2 | Efficacy of Immunotherapy Plus a Drug in Patients With Progressive Advanced Mucosal Cancer of Different Locations | October 28, 2020 | January 2025 |
| NCT05538572 | Active, not recruiting | Phase 1 | A Study of PRT3645 in Participants With Select Advanced or Metastatic Solid Tumors | December 27, 2022 | December 2024 |
| NCT04297995 | Active, not recruiting | Phase 2 | Evaluate the Efficacy and Safety of HLX10 in Combination With HLX07 in Patients With Advanced Head and Neck Tumors | July 29, 2020 | June 30, 2025 |
| NCT04234113 | Active, not recruiting | Phase 1 | Study of SO-C101 and SO-C101 in Combination With Pembro in Adult Patients With Advanced/Metastatic Solid Tumors | June 13, 2019 | November 2024 |
| NCT04213404 | Active, not recruiting | Phase 1 | Ribociclib and Spartalizumab in R/M HNSCC | March 13, 2020 | January 2025 |
| NCT04199104 | Active, not recruiting | Phase 3 | A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (LEAP-010) (MK-7902-010) | February 5, 2020 | December 23, 2024 |
| NCT05432193 | Active, not recruiting | Phase 1 | FAPi Radioligand OpeN-Label, Phase 1 Study to Evaluate Safety, Tolerability and DosImetry of [Lu-177]-PNT6555; A Dose Escalation Study for TReatment of Patients With Select Solid Tumors (FRONTIER) | July 13, 2022 | December 2026 |
| NCT02777385 | Active, not recruiting | Phase 2 | Pembrolizumab in Combination With Cisplatin and Intensity Modulated Radiotherapy (IMRT) in Head and Neck Cancer | May 31, 2016 | June 30, 2026 |
| NCT01154920 | Active, not recruiting | Phase 2 | Paclitaxel, Carboplatin and Cetuximab (PCC) With Cetuximab, Docetaxel, Cisplatin and Fluorouracil (C-TPF) in Previously Untreated Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma | July 9, 2010 | December 31, 2025 |
| NCT06307093 | Active, not recruiting | Phase 1 | Study Comparing the Pharmacokinetics, Safety, and Efficacy of RPH-075 and Keytruda® in Patients With Malignant Neoplasms | March 1, 2023 | July 2025 |
| NCT02270814 | Active, not recruiting | Phase 2 | Cisplatin, Nab-Paclitaxel, and Cetuximab (CACTUX) in Patients With Incurable Head and Neck Squamous Cell Carcinoma | February 2, 2015 | December 31, 2024 |
| NCT04074967 | Active, not recruiting | Phase 1/Phase 2 | Study of ARRY-614 Plus Either Nivolumab or Nivolumab+Ipilimumab | June 11, 2020 | November 21, 2027 |
| NCT04001543 | Active, not recruiting | N/A | Efficacy of an Oral Immunomodulatory Nutrient on Survival During Postoperative Concomitant Chemoradiotherapy in Head and Neck Cancer | March 14, 2019 | May 2026 |
| NCT03983954 | Active, not recruiting | Phase 1 | Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumors | October 10, 2019 | October 1, 2026 |
| NCT03953443 | Active, not recruiting | Expression & Epigenetic Silencing of MicroRNA for Predicting Therapeutic Response and Prognosis of HPV-negative HNSCC | December 17, 2010 | December 31, 2026 | |
| NCT05322135 | Active, not recruiting | Early Phase 1 | A Pilot Study of Glutamine PET Imaging of Head and Neck Squamous Cell Carcinoma | September 14, 2022 | March 20, 2025 |
| NCT03838601 | Active, not recruiting | N/A | Role of Microbiome as a Biomarkers in Locoregionally-Advanced Oropharyngeal Squamous Cell Carcinoma 2 | July 2, 2019 | March 2025 |
| NCT01644786 | Active, not recruiting | The Head and Neck Tumor Biobank | August 2012 | August 2028 | |
| NCT04969315 | Active, not recruiting | Phase 1/Phase 2 | TT-10 as a Single Agent in Subjects With Advanced Selected Solid Tumors | June 23, 2023 | August 14, 2025 |
| NCT03049618 | Active, not recruiting | Phase 2 | Recombinant EphB4-HSA Fusion Protein and Pembrolizumab, MK-3475 | March 10, 2017 | March 10, 2026 |
| NCT03775525 | Active, not recruiting | Phase 1 | Study Evaluating GZ17-6.02 in Patients With Advanced Solid Tumors or in Combination With Capecitabine in Metastatic Hormone Receptor Positive Breast Cancer | March 1, 2019 | December 2023 |
| NCT03070366 | Active, not recruiting | Phase 2 | Stereotactic Radiotherapy Combined With Chemotherapy or Not for Treatment of Oligometastases in HNSCC | September 21, 2015 | July 2026 |
| NCT03082534 | Active, not recruiting | Phase 2 | Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma | March 28, 2017 | May 2024 |
| NCT03650764 | Active, not recruiting | Phase 1/Phase 2 | Ramucirumab + Pembrolizumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma | May 29, 2019 | December 31, 2024 |
| NCT03552718 | Active, not recruiting | Phase 1 | QUILT-2.025 NANT Neoepitope Yeast Vaccine (YE-NEO-001): Adjuvant Immunotherapy Using a Personalized Neoepitope Yeast-Based Vaccine To Induce T-Cell Responses In Subjects W/ Previously Treated Cancers. | August 10, 2018 | December 30, 2025 |
| NCT03519048 | Active, not recruiting | Phase 3 | Multicentric Comparative Study Between a Conventional and an Intensive Follow up Strategy After Treatment of a Head and Neck Squamous Cell Carcinoma | January 17, 2018 | January 2031 |
| NCT04854499 | Active, not recruiting | Phase 2 | Study of Magrolimab Combination Therapy in Patients With Head and Neck Squamous Cell Carcinoma | September 7, 2021 | July 2025 |
| NCT03498378 | Active, not recruiting | Phase 1 | Avelumab, Cetuximab, and Palbociclib in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | June 6, 2018 | December 2024 |
| NCT02432963 | Active, not recruiting | Phase 1 | Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy | June 14, 2016 | December 31, 2024 |
| NCT03195699 | Active, not recruiting | Phase 1 | Oral STAT3 Inhibitor, TTI-101, in Patients With Advanced Cancers | November 15, 2017 | December 1, 2024 |
| NCT03412058 | Active, not recruiting | N/A | Identifying the Predictive Factors of Response to PD-1 or PD-L1 Antagonists | June 27, 2018 | December 2025 |
| NCT04752384 | Active, not recruiting | Phase 2 | Transdermal Buprenorphine for the Treatment of Radiation-Induced Mucositis Pain in Head and Neck Cancer Patients | July 8, 2021 | September 2025 |
| NCT03212469 | Active, not recruiting | Phase 1/Phase 2 | A Trial of Durvalumab and Tremelimumab in Combination With SBRT in Patients With Metastatic Cancer | June 20, 2017 | December 2024 |
| NCT03228667 | Active, not recruiting | Phase 2 | QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors | December 11, 2018 | December 2024 |
| NCT03236935 | Active, not recruiting | Phase 1 | Phase Ib of L-NMMA and Pembrolizumab | August 3, 2018 | December 28, 2023 |
| NCT03247712 | Active, not recruiting | Phase 1/Phase 2 | Neoadjuvant Immunoradiotherapy in Head & Neck Cancer | January 15, 2018 | December 2026 |
| NCT03258554 | Active, not recruiting | Phase 2/Phase 3 | Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin | April 3, 2018 | September 21, 2024 |
| NCT04694846 | Active, not recruiting | N/A | Effectiveness of an Enhanced Tobacco Intervention Protocol Compared to Standard Treatment in Helping Head and Neck and Lung Cancer Patients Starting Treatment to Reduce Cigarette Use | August 19, 2020 | August 16, 2024 |
| NCT04599309 | Active, not recruiting | Real-time Detection of ctDNA and/or HPV DNA in High-risk Locally-advanced Head and Neck Squamous Cell Carcinoma | October 15, 2020 | December 31, 2024 | |
| NCT03283605 | Active, not recruiting | Phase 1/Phase 2 | Immunotherapy and SBRT for Metastatic Head and Neck Carcinomas | July 17, 2018 | December 2023 |
| NCT03389477 | Active, not recruiting | Phase 2 | Los Tres Paso: Neoadjuvant Palbociclib Monotherapy, Concurrent Chemoradiation Therapy, Adjuvant Palbociclib Monotherapy in Patients With p16INK4a Negative, HPV-Unrelated Head and Neck Squamous Cell Carcinoma | April 27, 2018 | April 6, 2027 |
| NCT05229601 | Active, not recruiting | Phase 1 | A Study of HFB301001 in Adult Patients With Advanced Solid Tumors | April 20, 2022 | January 2025 |
| NCT03336606 | Active, not recruiting | Phase 1 | Study of MEDI0562 Prior to Surgical Resection in Head and Neck Squamous Cell Carcinoma (HNSCC) or Melanoma | July 25, 2018 | December 1, 2025 |
| NCT04555837 | Active, not recruiting | Phase 1/Phase 2 | Alisertib and Pembrolizumab for the Treatment of Patients With Rb-deficient Head and Neck Squamous Cell Cancer | September 15, 2020 | May 30, 2025 |
| NCT03340896 | Active, not recruiting | Phase 3 | Trial of Laryngeal Preservation Comparing Induced CT Followed by RT vs CT Concomitant to RT | June 25, 2015 | November 2028 |
| NCT03370276 | Active, not recruiting | Phase 1/Phase 2 | Cetuximab & Nivolumab in Patients With Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma | December 20, 2017 | August 2024 |
| NCT03386357 | Active, not recruiting | Phase 2 | Radiotherapy With Pembrolizumab in Metastatic HNSCC | July 20, 2018 | January 2026 |
| NCT05551117 | Active, not recruiting | Phase 2 | A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors | June 13, 2023 | May 2027 |
| NCT05523323 | Active, not recruiting | Phase 3 | A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (LEAP-010) (MK-7902-010)-China Extension Study | October 30, 2020 | March 1, 2025 |
| NCT00174837 | Completed | Phase 3 | TRACE: Tirapazamine-Radiation And Cisplatin Evaluation | April 2005 | January 2008 |
| NCT00620139 | Completed | Proximal Molecular Effects of Concurrent Chemoradiotherapy on Head and Neck Squamous Cell Carcinoma | March 2005 | October 2013 | |
| NCT00765791 | Completed | N/A | 2B or Not 2B? Shoulder Function After Level 2B Neck Dissection: A Randomized Controlled Study | December 2008 | June 2017 |
| NCT00894413 | Completed | Phase 2 | A Trial of Tadalafil in Patients With Squamous Cell Carcinoma of the Upper Aero Digestive Tract | May 8, 2007 | March 2012 |
| NCT00957853 | Completed | Phase 2 | Preoperative Treatment With Cetuximab and/or IMC-A12 | October 17, 2011 | August 15, 2018 |
| NCT01045421 | Completed | Phase 1/Phase 2 | Alisertib in Adults With Nonhematological Malignancies, Followed by Alisertib in Lung, Breast, Head and Neck or Gastroesophageal Malignancies | February 2010 | April 2014 |
| NCT01086826 | Completed | Phase 3 | Treatment of Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck | March 2008 | December 2014 |
| NCT01172769 | Completed | Phase 2 | Efficacy Study of Temsirolimus to Treat Head and Neck Cancer | June 2010 | March 2012 |
| NCT01280318 | Completed | Phase 1/Phase 2 | Profile of Plasma Growth Factors Before and After Head and Neck Oncological or Non-oncological Surgery | January 2009 | September 2012 |
| NCT01425736 | Completed | Phase 2 | Nimotuzumab in Combination With TPF(Cisplatin ,Fluorouracil and Docetaxel) for Head and Neck Squamous Cell Carcinoma | January 2009 | March 2013 |
| NCT01427478 | Completed | Phase 3 | Evaluation of Afatinib in Maintenance Therapy in Squamous Cell Carcinoma of the Head and Neck | September 2011 | May 2021 |
| NCT01469546 | Completed | Phase 2 | Phase II Trial Evaluating Axitinib In Patients With Unresectable, Recurrent Or Metastatic Head And Neck Cancer | January 2012 | March 2016 |
| NCT01484847 | Completed | N/A | A Study of PF-00299804 When Given Through a Feeding Tube in Locally Advanced Head and Neck Squamous Cell Carcinoma | December 2011 | July 2015 |
| NCT01515137 | Completed | Phase 1 | Study of TARCEVA (Erlotinib) as Adjuvant Treatment for Locally Advanced Head and Neck Squamous Cell Carcinoma | November 2005 | September 2014 |
| NCT01581970 | Completed | Phase 2 | Potentiation of Cetuximab by Tregs Depletion With CSA in Advanced Head & Neck Cancer | June 2012 | September 2015 |
| NCT01696955 | Completed | Phase 2 | Cetuximab With or Without Tivantinib in Treating Patients With Head and Neck Cancer That Is Recurrent, Metastatic, or Cannot Be Removed by Surgery | August 20, 2012 | May 5, 2017 |
| NCT01697800 | Completed | Phase 2 | A Phase II Trial of Tadalafil in Patients With Squamous Cell Carcinoma of the Upper Aero Digestive Tract | September 2012 | July 14, 2014 |
| NCT01711541 | Completed | Phase 1/Phase 2 | Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IV Head and Neck Cancer | October 22, 2012 | May 15, 2023 |
| NCT01727076 | Completed | Phase 1 | Recombinant Interleukin-15 in Treating Patients With Advanced Melanoma, Kidney Cancer, Non-small Cell Lung Cancer, or Squamous Cell Head and Neck Cancer | February 15, 2013 | June 30, 2016 |
| NCT01794481 | Completed | N/A | Benefits of Exercise Training in Head and Neck Cancer Patients Undergoing Organ-Preserving Definitive Therapy | January 2010 | March 2015 |
| NCT01807546 | Completed | Phase 2 | Oral Rigosertib for Squamous Cell Carcinoma | March 2013 | April 2016 |
| NCT01846091 | Completed | Phase 1 | Viral Therapy In Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Cancer or Metastatic Breast Cancer | April 9, 2013 | November 26, 2019 |
| NCT01864850 | Completed | Phase 3 | Non Inferiority Trial of Standard RT Versus Hypofractionated Split Course in Elderly Vulnerable Patients With HNSCC | October 18, 2013 | June 5, 2020 |
| NCT01950689 | Completed | Phase 3 | NIMRAD (A Randomised Placebo-controlled Trial of Synchronous NIMorazole Versus RADiotherapy Alone in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma Not Suitable for Synchronous Chemotherapy or Cetuximab) | September 11, 2014 | January 7, 2021 |
| NCT02003482 | Completed | Prospective Trial of Serial CT Imaging for Evaluation of Dosimetric/Volumetric Changes During IMRT for Head/Neck Cancer | May 9, 2006 | March 26, 2018 | |
| NCT02024035 | Completed | Protocole Advanced RadioTherapy ORL | November 2009 | November 2013 | |
| NCT02047201 | Completed | Phase 2 | Assessing Tumor Response and IMRT Treat Plan After IC Based on FDG-PET/CT for Locally Advanced HNSCC | June 2013 | January 2016 |
| NCT02178072 | Completed | Phase 1 | Window Trial 5-aza in HNSCC, T-tare | February 19, 2015 | October 23, 2019 |
| NCT02207439 | Completed | Phase 2 | Phase II Trial of Nelfinavir With Concurrent Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck | July 2014 | May 2022 |
| NCT02255097 | Completed | Phase 2 | Study of MK-3475 (Pembrolizumab) in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma After Treatment With Platinum-based and Cetuximab Therapy (MK-3475-055/KEYNOTE-055) | October 24, 2014 | June 18, 2021 |
| NCT02268695 | Completed | Phase 2 | Platinum-Cetuximab Combined With Docetaxel or With 5FU in Patients With Recurrent/Metastatic HNSCC | October 10, 2014 | December 31, 2021 |
| NCT02279459 | Completed | Dual-Energy CT in Patients With Head and Neck Squamous Cell Carcinomas | April 14, 2015 | April 15, 2019 | |
| NCT02318771 | Completed | Phase 1 | Radiation Therapy and MK-3475 for Patients With Recurrent/Metastatic Head and Neck Cancer, Renal Cell Cancer, Melanoma, and Lung Cancer | February 5, 2015 | March 25, 2021 |
| NCT02508246 | Completed | Phase 1 | WEE1 Inhibitor MK-1775, Docetaxel, and Cisplatin Before Surgery in Treating Patients With Borderline Resectable Stage III-IVB Squamous Cell Carcinoma of the Head and Neck | July 22, 2015 | April 26, 2018 |
| NCT02531906 | Completed | Phase 1 | Gabapentin, Methadone Hydrochloride, and Oxycodone Hydrochloride in Improving Quality of Life in Patients With Stage II-IV Head and Neck Cancer During Chemoradiation | April 24, 2015 | June 14, 2018 |
| NCT02538510 | Completed | Phase 1/Phase 2 | Pembrolizumab and Vorinostat in Treating Patients With Recurrent Squamous Cell Head and Neck Cancer or Salivary Gland Cancer That Is Metastatic and/or Cannot Be Removed by Surgery | October 8, 2015 | September 15, 2023 |
| NCT02544880 | Completed | Phase 1 | PDE5 Inhibition Via Tadalafil to Enhance Anti-Tumor Mucin 1 (MUC1) Vaccine Efficacy in Patients With HNSCC | April 25, 2016 | June 8, 2021 |
| NCT02608736 | Completed | Early Phase 1 | Chemoprevention of Head and Neck Squamous Cell Carcinoma (HNSCC) With Valproic Acid | December 2015 | July 2017 |
| NCT02643303 | Completed | Phase 1/Phase 2 | A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers | December 28, 2016 | February 23, 2022 |
| NCT02752932 | Completed | N/A | TumorGraft- Guided Therapy for Improved Outcomes in Head and Neck Squamous Cell Cancer- A Feasibility Study | November 2015 | October 12, 2017 |
| NCT02778191 | Completed | Comparison of Concomitant Cisplatin Versus Carboplatin and 5-fluorouracil With Radiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma | February 2016 | March 2017 | |
| NCT02794675 | Completed | Early Phase 1 | Intraoperative Placement of Cesium-131 Permanent Interstitial Brachytherapy in Head and Neck Cancer | December 21, 2016 | July 24, 2020 |
| NCT02862678 | Completed | N/A | Predictive Value of Diffusion-weighted MRI Performed in Early Post-treatment in the Occurrence of Tumor Recurrence or Progression in Head and Neck Squamous Cell Carcinoma Treated With Chemoradiotherapy: a Pilot Study | April 2014 | April 23, 2019 |
| NCT02949700 | Completed | Phase 1/Phase 2 | Phase I/II Study OF Metformin in Combination With Cisplatin and Radiation in Head and Neck Squamous Cell Carcinoma | January 26, 2017 | July 7, 2022 |
| NCT02999646 | Completed | N/A | Personalized and Cell-based Antitumor Immunization MVX-ONCO-1 in Advanced HNSCC | July 25, 2018 | June 29, 2023 |
| NCT03022409 | Completed | Phase 1 | A Study to Investigate Biomarker Effects of Pre-Surgical Treatment With DNA Damage Repair (DDR) Agents in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC). | September 18, 2017 | January 20, 2021 |
| NCT03153982 | Completed | Phase 2 | Ruxolitinib in Operable Head and Neck Cancer | June 8, 2018 | October 18, 2023 |
| NCT03182959 | Completed | Early Phase 1 | Broccoli Sprout Extract in Preventing Recurrence in Patients With Tobacco-Related Head and Neck Squamous Cell Cancer | April 24, 2017 | January 19, 2021 |
| NCT03212157 | Completed | N/A | GlucoCEST MRI in Oncology | January 6, 2017 | October 8, 2019 |
| NCT03267121 | Completed | Phase 2 | A Study of Apatinib and Tegafur Gimeracil Oteracil in Locally Advanced Squamous Cell Carcinoma of the Head and Neck | October 1, 2017 | November 1, 2020 |
| NCT03281499 | Completed | N/A | Transoral Robotic Surgery and Tailored Radiotherapy in Unknown Primary and Small Squamous Cell Head and Neck Cancer | August 15, 2017 | July 19, 2022 |
| NCT03319459 | Completed | Phase 1 | FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors | January 18, 2018 | December 15, 2020 |
| NCT03340038 | Completed | N/A | Use of a Non-ICU Specialty Ward For Immediate Post-operative Management of Head and Neck Free Flaps | April 10, 2016 | April 16, 2019 |
| NCT03405142 | Completed | Phase 2 | Panitumumab-IRDye800 Compared to Sentinel Node Biopsy and (Selective) Neck Dissection in Identifying Metastatic Lymph Nodes in Patients With Head&Neck Cancer | August 1, 2019 | April 27, 2021 |
| NCT03421912 | Completed | N/A | Satisfaction and Quality of Life Comparison Between Patients Using Cicaplast Baume B5 Versus Dexeryl for the Management of Cutaneous Toxicities Induced by Epidermal Growth Factor Receptor Inhibitors (iEGFR) | February 16, 2018 | May 11, 2021 |
| NCT03433027 | Completed | Phase 2 | A Study of BB-401 in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | March 15, 2018 | April 6, 2020 |
| NCT03518671 | Completed | N/A | Building a Renewed ImaGe After Head & Neck Cancer Treatment | February 8, 2018 | August 22, 2019 |
| NCT03524326 | Completed | Phase 1 | Testing Lenvatinib and Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma and Cutaneous Squamous Cell Carcinoma | April 30, 2018 | October 13, 2022 |
| NCT03618654 | Completed | Early Phase 1 | Durvalumab With or Without Metformin in Treating Participants With Head and Neck Squamous Cell Carcinoma | November 1, 2018 | December 7, 2022 |
| NCT03665285 | Completed | Phase 1/Phase 2 | A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors | October 1, 2018 | April 11, 2023 |
| NCT03666273 | Completed | Phase 1 | Phase 1 Study of BAY1905254 - An Early Clinical Research Study to Evaluate a New Drug Called Bapotulimab (BAY1905254) in the Expansion Cohort in Combination With Pembrolizumab in Head and Neck Cancer That Has Returned or is Discovered to be Metastatic and is Expressing PDL1. | September 12, 2018 | May 15, 2024 |
| NCT03735680 | Completed | Phase 2 | A Study to Evaluate ONM-100, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer | August 9, 2019 | November 18, 2021 |
| NCT03878979 | Completed | Phase 2 | Preoperative Immune Checkpoint Inhibitor for Patients With Primary Untreated or Recurrent/Metastatic SCCHN | July 8, 2019 | October 17, 2023 |
| NCT03953976 | Completed | Phase 2 | INRT-AIR: A Prospective Phase II Study of Involved Nodal Radiation Therapy | July 23, 2019 | January 22, 2024 |
| NCT03998696 | Completed | Phase 4 | An Experimental Study to Compare Treatment Response and Toxicities of Concurrent Chemoradiation With Weekly Cisplatin and Three Weekly Cisplatin in Locally Advanced Head and Neck Cancer. | July 1, 2017 | December 31, 2018 |
| NCT04253808 | Completed | N/A | Feasibility of a Carbohydrate-restricted, High-fat Diet on Head and Neck Squamous Cell Carcinoma Outcomes | February 3, 2020 | August 10, 2021 |
| NCT04260074 | Completed | Epigenetic Changes in Head and Neck Cancer | March 11, 2020 | July 14, 2021 | |
| NCT04413214 | Completed | Phase 1 | Carrimycin in Patients With Locally Advanced, Recurrent, or Metastatic HNSCC (Non NPC): A Phase I Trial | December 20, 2019 | December 30, 2022 |
| NCT04452214 | Completed | Phase 1 | A Study of the Safety and Tolerance of CAN04 and Pembrolizumab in Combination With and Without Carboplatin and Pemetrexed in Subjects With Solid Tumors | September 24, 2020 | June 28, 2023 |
| NCT04525066 | Completed | Phase 2 | Phonosurgical Augmentation After Laser Resection of Early Glottic Carcinoma | August 13, 2013 | August 13, 2018 |
| NCT04616196 | Completed | Phase 1/Phase 2 | Study of NKTR 255 in Combination With Cetuximab in Solid Tumors | October 30, 2020 | March 30, 2023 |
| NCT04724096 | Completed | Evaluation of OE-MRI in Patients With H&N Cancer | March 4, 2021 | February 1, 2023 | |
| NCT04857164 | Completed | Phase 2 | Study of Pembrolizumab Combined With Chemotherapy in the First Line Therapy for R/M HNSCC in China | April 30, 2021 | March 2, 2024 |
| NCT05918224 | Completed | Phase 2 | Streptococcus Salivarius K12 for Prevention and Treatment of Oral Mucositis in Patients Undergoing Radiotherapy | January 1, 2022 | November 30, 2022 |
| NCT05936502 | Completed | Ascertaining the Radiologic Prognostic Importance of Extranodal Extension on Imaging (iENE) in Head and Neck Cancer | July 11, 2022 | September 30, 2023 | |
| NCT06062602 | Completed | Early Phase 1 | PBI-MST-01(NCT04541108) Substudy TAK-02: Intratumoral Microdosing of TAK-676 in HNSCC | July 26, 2021 | November 15, 2022 |
| NCT06413095 | Completed | Early Phase 1 | PBI-MST-01 (NCT04541108) Substudy MSD-03: Intratumoral Microdosing of Pembrolizumab Alone and With MK-0482 or MK-4830 in HNSCC or STS | June 1, 2022 | June 22, 2023 |
| NCT05668949 | Not yet recruiting | Phase 1/Phase 2 | Phase I/II Open Label Study Evaluating the Safety and Efficacy of Combining STAT3 Inhibition (TTI-101) With Anti-PD-1 Therapy (Pembrolizumab) in Patients With Recurrent or Metastatic (RM) Head and Neck Squamous Cell Carcinoma (HNSCC) | June 30, 2024 | August 12, 2026 |
| NCT05582590 | Not yet recruiting | Phase 1 | Autologous T Cells Targeting HPV16 HPV18 & Survivin in Patients With R/R HPV-related Oropharyngeal Cancers | March 31, 2025 | August 25, 2027 |
| NCT05351762 | Not yet recruiting | Phase 2 | Nimotuzumab Combined With Neoadjuvant Chemotherapy in the Treatment of Resectable LA HNSCC | July 1, 2022 | July 30, 2024 |
| NCT05189184 | Not yet recruiting | Phase 2 | Study of Camrelizumab in Combination With Apatinib Mesylate Plus Albumin-bound Paclitaxel and Cisplatin as the First Line Treatment of Recurrent or Metastatic, UnresectableHead and Neck Squamous Cell Carcinoma | March 30, 2022 | March 30, 2025 |
| NCT06159621 | Not yet recruiting | Phase 1 | CD40 Agonist and PD-1 Inhibitor in HNSCC | July 1, 2024 | March 1, 2028 |
| NCT05136768 | Not yet recruiting | Phase 2 | Sintilimab Combined With Chemotherapy and SBRT in Limited Metastatic Head and Neck Squamous Cell Carcinoma (LM-HNSCC) | December 2021 | December 2024 |
| NCT05065346 | Not yet recruiting | N/A | Neoadjuvant DaRT for Locally Advanced Oral Cavity SCC | March 2025 | June 2026 |
| NCT06289049 | Not yet recruiting | Phase 2 | Heavy Strength Training in Head and Neck Cancer Survivors | September 2024 | April 2026 |
| NCT06147037 | Not yet recruiting | Phase 1 | A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours | June 28, 2024 | December 30, 2027 |
| NCT06251050 | Not yet recruiting | Phase 1/Phase 2 | A Lithium-containing Mouthwash Prevention and Treatment of Oral Mucositis and Dysgeusia in Patients Undergoing Radiotherapy | March 1, 2024 | January 31, 2025 |
| NCT05024019 | Not yet recruiting | Phase 2 | Nimotuzumab Combined With Radiotherapy in High-risk Patients With HNSCC Not Suitable for Cisplatin After Surgery | August 21, 2021 | August 21, 2025 |
| NCT06437522 | Not yet recruiting | Phase 2 | A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors | June 2024 | June 2026 |
| NCT06100497 | Not yet recruiting | Phase 2 | Efficacy and Safety of PD-1 Plus Chemotherapy in Poorly Differentiated Locally Advanced (LA) HNSCC | November 1, 2023 | October 31, 2028 |
| NCT06422403 | Not yet recruiting | Phase 2 | A Value-Driven Study on Reducing Immune Checkpoint Inhibitor Dosing Frequency in Advanced Cancers | July 1, 2024 | December 31, 2029 |
| NCT06465069 | Not yet recruiting | Phase 1 | A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors | June 2024 | May 2027 |
| NCT06199271 | Not yet recruiting | Phase 2 | Neoadjuvant Adebrelimab Plus Dalpiciclib in Head and Neck Squamous Cell Carcinoma | January 31, 2024 | December 31, 2026 |
| NCT06084845 | Not yet recruiting | Phase 2 | Testing the Addition of an Investigational Drug, Xevinapant, to Usual Radiation Therapy Plus Cisplatin/Carboplatin for Patients With Head and Neck Cancer | April 12, 2024 | May 31, 2028 |
| NCT06383507 | Not yet recruiting | Phase 1 | A Clinical Study of Anti-CD70 UCAR-T in Relapsed or Refractory Solid Tumors | April 22, 2024 | April 21, 2029 |
| NCT06194656 | Not yet recruiting | Phase 2 | Clinical Trial of SIBP-03 in Patients With Head and Neck Squamous Cell Carcinoma | December 28, 2023 | May 30, 2025 |
| NCT06366945 | Not yet recruiting | Phase 2 | Tirelizumab in Combination With Carboplatin and Polymeric Micellar Paclitaxel for Neoadjuvant Therapy in cN+ HNSCC | April 20, 2024 | May 30, 2029 |
| NCT06357858 | Not yet recruiting | Phase 1 | ASTX727 and Nivolumab in Squamous Cell Carcinoma of the Head and Neck | June 1, 2024 | February 28, 2026 |
| NCT06016413 | Not yet recruiting | Phase 2 | Adelbelimab Combination Chemotherapy in Neoadjuvant Therapy for Squamous Cell Carcinoma of the Head and Neck | September 1, 2023 | December 1, 2026 |
| NCT05993858 | Not yet recruiting | Phase 2 | Neoadjuvant PD-1 Inhibitor Combined With Cetuximab in Operable Locally Advanced HNSCC | October 20, 2023 | December 20, 2026 |
| NCT02990936 | Not yet recruiting | Prognostic Impact of Tumor Growth Velocity in Head and Neck Squamous Cell Carcinoma Treated by Radio(Chemo)Therapy | November 1, 2019 | November 2026 | |
| NCT03865277 | Not yet recruiting | Phase 2 | Individualized Radiation Dose Prescription in HNSCC Based on F-MISO-PET Hypoxia-Imaging | July 1, 2024 | September 30, 2027 |
| NCT05965154 | Not yet recruiting | Phase 2 | Calizumab Combined With Bevacizumab and Capecitabine in the Treatment of Head and Neck Squamous Cell Carcinoma | August 1, 2023 | June 1, 2025 |
| NCT06444815 | Not yet recruiting | Phase 1 | A Study of VET3-TGI in Patients With Solid Tumors | August 1, 2024 | December 31, 2027 |
| NCT06444009 | Not yet recruiting | Phase 2 | A Phase II Study of Neoadjuvant Immunotherapy in Combination With Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma | June 1, 2024 | December 1, 2027 |
| NCT05879484 | Not yet recruiting | Phase 1/Phase 2 | Study of Front Line Pembrolizumab and Valemetostat in PD-L1 Positive, HPV-Negative Recurrent/Metastatic Squamous Cell Carcinoma (SCC) of the Head and Neck: The PANTHERAS | June 23, 2024 | July 1, 2027 |
| NCT06142318 | Recruiting | Phase 2 | Pirfenidone as a Radiosensitizer in the Treatment of Head and Neck Squamous Cell Carcinoma | November 15, 2023 | June 30, 2025 |
| NCT06308913 | Recruiting | Early Phase 1 | Pembrolizumab, INCB081776, and Radiation Therapy for Head and Neck Squamous Cell Carcinoma | June 15, 2024 | July 31, 2027 |
| NCT03740256 | Recruiting | Phase 1 | Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors | December 14, 2020 | December 30, 2038 |
| NCT03789097 | Recruiting | Phase 1/Phase 2 | Vaccination With Flt3L, Radiation, and Poly-ICLC | April 5, 2019 | March 2025 |
| NCT03795610 | Recruiting | Phase 2 | Window of Opportunity Study of IPI-549 in Patients With Locally Advanced HPV+ and HPV- Head and Neck Squamous Cell Carcinoma | March 6, 2020 | June 2023 |
| NCT03809624 | Recruiting | Phase 2 | Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer | January 30, 2019 | December 2025 |
| NCT03817307 | Recruiting | N/A | Validation of USPIO-enhanced MRI for Detection of Lymph Node Metastases in Head and Neck Carcinoma | May 20, 2019 | April 2023 |
| NCT06323369 | Recruiting | Phase 2 | Tislelizumab Combined With Chemotherapy Followed by Surgery Versus Up-front Surgery in Resectable Clinically Node-negative Head and Neck Squamous Cell Carcinoma | March 25, 2024 | September 25, 2029 |
| NCT03916627 | Recruiting | Phase 2 | Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC in Adult Patients | July 23, 2019 | February 26, 2031 |
| NCT03942380 | Recruiting | N/A | Cell-free Tumor DNA in Head and Neck Cancer Patients | February 1, 2017 | February 1, 2025 |
| NCT06332092 | Recruiting | Phase 2 | FID-007 and Cetuximab in Treating Patients With Advanced Head and Neck Squamous Cell Carcinoma | April 10, 2024 | December 31, 2025 |
| NCT03993353 | Recruiting | Phase 2 | Tadalafil and Pembrolizumab in Recurrent or Metastatic Head and Neck Cancer | April 7, 2020 | March 1, 2029 |
| NCT06338657 | Recruiting | Phase 1 | FID-007 Followed by Standard of Care Surgery in Head and Neck Cancer | April 1, 2024 | April 1, 2027 |
| NCT04096638 | Recruiting | Phase 1 | Safety and Efficacy of SB 11285 Alone and in Combination With Atezolizumab in Patients With Advanced Solid Tumors | September 23, 2019 | March 2027 |
| NCT04119024 | Recruiting | Phase 1 | Gene Modified Immune Cells (IL13Ralpha2 CAR T Cells) After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors | November 27, 2019 | October 1, 2025 |
| NCT04121286 | Recruiting | Phase 1 | A Study of JAB-3312 in Adult Patients With Advanced Solid Tumors in China | June 10, 2020 | December 2023 |
| NCT04139057 | Recruiting | Phase 1/Phase 2 | EBV-Specific Anti-PD1 TCR-T Cells in the Treatment of EBV-Positive NHSCC | March 1, 2019 | January 1, 2024 |
| NCT04152499 | Recruiting | Phase 1/Phase 2 | Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies | February 28, 2020 | December 2025 |
| NCT04196985 | Recruiting | N/A | 18F-FDG PET/CT Versus 18F-FDG PET/MRI in Detecting Locoregional Recurrence 3 Months After CRT in Head and Neck SCC | October 1, 2020 | October 1, 2024 |
| NCT02734537 | Recruiting | Phase 2 | Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery | November 23, 2016 | December 31, 2027 |
| NCT02678884 | Recruiting | N/A | Head and Neck Squamous Cell Carcinoma (HNSCC)PET-CT Pilot Study | October 2014 | November 2028 |
| NCT05296135 | Recruiting | Predicting Immunotherapy Efficacy in Head and Neck Squamous Cell Cancer | February 5, 2020 | April 1, 2024 | |
| NCT05338905 | Recruiting | N/A | Intensive Symptom Surveillance Guided by Machine Learning-Directed Risk Stratification in Patients With Non-Metastatic Head and Neck Cancer, The INSIGHT Trial | September 26, 2022 | October 30, 2025 |
| NCT05343325 | Recruiting | Phase 2 | The Efficacy and Safety of Neoadjuvant Low-dose Radiotherapy Combined With Chemoimmunotherapy in Locally Advanced HNSCC | March 9, 2022 | March 31, 2027 |
| NCT05364411 | Recruiting | N/A | HYpofractionated, Dose-redistributed RAdiotherapy With Protons and Photons in HNSCC | October 10, 2022 | June 1, 2026 |
| NCT05400239 | Recruiting | SOTO: Treatment Sensitivity of Organoids to Predict Treatment Outcome | June 1, 2022 | June 30, 2025 | |
| NCT05420948 | Recruiting | Phase 2 | A Study of Pembrolizumab in Combination With Chemotherapy for Head and Neck Cancer | October 17, 2022 | December 1, 2026 |
| NCT05433116 | Recruiting | Phase 2 | Pembrolizumab and Lenvatinib After Definitive Chemoradiation of Locally Advanced HNSCC | May 25, 2023 | September 2026 |
| NCT05437380 | Recruiting | N/A | Peritumoral Microbubbles and CEUS for SLN Detection and Biopsy in HNSCC | September 20, 2022 | June 28, 2026 |
| NCT05446467 | Recruiting | Phase 2 | Pembrolizumab in Combination With Low-dose PFas Neoadjuvant Treatment for Locally Advanced HNSCC | September 1, 2022 | March 1, 2026 |
| NCT05451576 | Recruiting | N/A | Sodium Selenite Supplementation in Patients With Head and Neck Cancer | August 12, 2020 | June 30, 2024 |
| NCT05457478 | Recruiting | N/A | The Use of "Smart" Body-Weight Scales for Weight and Nutritional Monitoring in Patients With Head and Neck Cancer Undergoing Radiation Therapy | January 13, 2023 | December 1, 2023 |
| NCT05476965 | Recruiting | Phase 2 | Selected De-escalation Radiotherapy for Postoperative Head and Neck Squamous Cell Carcinoma | January 1, 2021 | June 2024 |
| NCT05499065 | Recruiting | Phase 2 | Real-time Margin Assessment in Head and Neck Cancer | March 1, 2023 | January 10, 2025 |
| NCT05516589 | Recruiting | Phase 2 | Neoadjuvant Chemotherapy, Tislelizumab With Afatinib for HNSCC | August 20, 2022 | August 19, 2024 |
| NCT05520099 | Recruiting | Observational Basket Trial to Collect Tissue to Train and Validate a Live Tumor Diagnostic Platform | June 26, 2023 | January 2027 | |
| NCT05522985 | Recruiting | Phase 2 | Neoadjuvant Chemotherapytreatment of Locally Advanced Head and Neck Squamous Cell Carcinoma | November 7, 2021 | November 7, 2024 |
| NCT05526924 | Recruiting | Phase 1 | Dosing Study of Radiation Combined With Tislelizumab and Pamiparib in Patients With Previously Treated Head and Neck Cancer | March 7, 2023 | January 1, 2026 |
| NCT05540899 | Recruiting | Phase 1 | Testing the Safety of Giving a Standard Dose of Radiation Over a Shorter Period of Time for Patients Who Had Surgery for Intermediate-Risk Head and Neck Cancer | November 8, 2023 | November 2028 |
| NCT05544136 | Recruiting | Phase 2 | A Study of Decreasing Radiation Therapy and Chemotherapy in People With Head and Neck Cancer | September 12, 2022 | March 12, 2027 |
| NCT05563272 | Recruiting | Phase 2 | 89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors | June 6, 2023 | December 29, 2025 |
| NCT05565417 | Recruiting | Phase 1/Phase 2 | Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas | November 28, 2022 | April 2025 |
| NCT05576077 | Recruiting | Phase 1 | A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors | January 17, 2023 | June 30, 2025 |
| NCT05576974 | Recruiting | Phase 2 | A Phase 2a, Single-dose, Open-label Study to Evaluate Diagnostic Performance and Safety of Pegsitacianine, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer, in Patients With Unknown Primary Head and Neck Cancer (ILLUMINATE STUDY) | April 17, 2024 | December 31, 2027 |
| NCT05585034 | Recruiting | Phase 1 | Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors | December 14, 2022 | December 2027 |
| NCT05635643 | Recruiting | Phase 1 | Study of CHS-114 in Participants With Advanced Solid Tumors | December 15, 2022 | February 2026 |
| NCT05645783 | Recruiting | Liquid Biopsy for Early DiagNosis of Squamous Cell Carcinoma of the HeAd and NeCk rEgion | February 1, 2023 | December 2024 | |
| NCT05674396 | Recruiting | Phase 2 | 3-5 FrAction Stereotactic Body Radiation Therapy for Palliation of Head and Neck Squamous Cell Carcinoma: the FAST Phase II Randomized Trial | June 30, 2023 | September 30, 2027 |
| NCT05707078 | Recruiting | N/A | PET/CT Follow up for Head and Neck Squamous Cell Carcinoma | March 7, 2023 | December 30, 2030 |
| NCT05714553 | Recruiting | Phase 1/Phase 2 | NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours | March 8, 2023 | January 2025 |
| NCT05726370 | Recruiting | Phase 2 | Preoperative Pembrolizumab and Chemotherapy in Resectable, Recurrent HNSCC | May 20, 2023 | May 20, 2030 |
| NCT05743569 | Recruiting | 3D Specimen Maps for RT Planning | January 26, 2023 | December 26, 2024 | |
| NCT05747625 | Recruiting | Phase 1 | (89Zr Panitumumab) With PET/CT for Diagnosing Metastases in Patients With Head and Neck Squamous Cell Carcinoma | May 9, 2023 | March 1, 2030 |
| NCT05784012 | Recruiting | Phase 1/Phase 2 | Two-cohort Study of Niraparib and Dostarlimab Plus (Chemo)RadIotherapy in Locally-Advanced Head and Neck Squamous Cell Carcinoma | November 8, 2023 | March 2029 |
| NCT05787535 | Recruiting | Phase 1 | HRYZ-T101 TCR-T Cell for HPV-18 Positive Advanced Solid Tumor | March 21, 2023 | September 2025 |
| NCT05793151 | Recruiting | N/A | Multi-Site Trial of Navigation vs Treatment as Usual for Delays in Starting Adjuvant Therapy | October 30, 2023 | March 30, 2028 |
| NCT05821751 | Recruiting | N/A | The Effect of Prebiotic Inulin on Patients Affected by R/M HNSCC Treated With Immune Checkpoint Inhibitors | December 2, 2021 | December 2, 2025 |
| NCT05827614 | Recruiting | Phase 1 | Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), in Subjects With Tumors With Oncogene Amplifications | March 24, 2023 | September 30, 2027 |
| NCT05854823 | Recruiting | N/A | The Efficacy and Safety of De-escalated Postoperative Radiotherapy in Locally Advanced HNSCC With pCR/MPR | April 10, 2023 | April 9, 2027 |
| NCT05858736 | Recruiting | Phase 1 | Safety, PK and Efficacy of AI-061 in Advanced Solid Tumors | July 11, 2023 | June 15, 2025 |
| NCT05859074 | Recruiting | Phase 1 | A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer | May 4, 2023 | May 4, 2028 |
| NCT05867303 | Recruiting | Phase 1 | A RC198 Study in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors | June 5, 2023 | September 30, 2024 |
| NCT05877599 | Recruiting | Phase 1 | A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation | July 27, 2023 | August 2039 |
| NCT05889091 | Recruiting | N/A | A Study of the Use of Fat Flap Reconstruction to Reduce Neck Injury After Cancer Treatment | May 16, 2023 | May 16, 2026 |
| NCT05901545 | Recruiting | Phase 1 | Evaluating 111In Panitumumab for Nodal Staging in Head and Neck Cancer | August 22, 2023 | November 30, 2029 |
| NCT05902988 | Recruiting | Phase 1/Phase 2 | A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer | October 18, 2023 | June 2026 |
| NCT05909904 | Recruiting | Phase 2 | Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell Carcinoma | July 21, 2023 | January 2027 |
| NCT05913388 | Recruiting | Phase 2 | GB1211 and Pembrolizumab Versus Pembrolizumab and Placebo in Patients With Metastatic Melanoma and Head and Neck Squamous Cell Carcinoma | February 29, 2024 | February 2030 |
| NCT05919290 | Recruiting | N/A | HN-QUEST: A Study of Head and Neck Imaging Biomarkers | July 26, 2023 | July 1, 2026 |
| NCT05941338 | Recruiting | Phase 2 | Tirelizumab in Combination With Carboplatin and Albumin-binding Paclitaxel for Neoadjuvant Therapy in HNSCC | March 1, 2023 | February 28, 2030 |
| NCT05945875 | Recruiting | Phase 1 | Evaluating the Use of Dual Imaging Techniques for Detection of Disease in Patients With Head and Neck Cancer | October 3, 2023 | December 31, 2028 |
| NCT05952947 | Recruiting | Phase 1 | HRYZ-T101 Injection for HPV18 Positive Solid Tumor | November 1, 2023 | February 2028 |
| NCT05964595 | Recruiting | Temporal Diffusion Spectroscopy MRI in Predicting the CPS of PD-L1 Expression and the Efficacy of Neoadjuvant Therapy | July 1, 2023 | December 31, 2025 | |
| NCT05977907 | Recruiting | Phase 2 | Neoadjuvant Pembrolizumab and IO102-103 for Squamous Cell Carcinoma of the Head and Neck (SCCHN). | December 14, 2023 | October 16, 2028 |
| NCT05996432 | Recruiting | Early Phase 1 | Image-Based, In-Vivo Assessment of Tumor Hypoxia to Guide Hypoxia-Driven Adaptive Radiation Therapy | May 17, 2023 | May 31, 2029 |
| NCT06006169 | Recruiting | Phase 2 | A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (Non-nasopharyngeal Carcinoma) and Other Solid Tumors | October 20, 2023 | October 2025 |
| NCT06007729 | Recruiting | Phase 2 | ARTEMIS-006: HS-20093 in Patients With Head and Neck Squamous Cell Carcinoma and Other Solid Tumors | December 18, 2023 | December 12, 2027 |
| NCT06011993 | Recruiting | Real-world Analysis on the Efficacy and Safety of Neoadjuvant Therapy for Head and Neck Squamous Cell Carcinoma （neoHNSCC） | July 19, 2023 | December 1, 2023 | |
| NCT06022029 | Recruiting | Phase 1 | A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas. | October 13, 2023 | August 29, 2026 |
| NCT06023875 | Recruiting | Phase 2 | Neoadjuvant Cadonilimab in Combination With Cisplatin and Nab-paclitaxel in Resectable Head and Neck Squamous Cell Carcinoma | July 19, 2023 | December 31, 2024 |
| NCT06047379 | Recruiting | Phase 1/Phase 2 | Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis | November 1, 2023 | August 31, 2026 |
| NCT06054477 | Recruiting | Phase 1/Phase 2 | Study of ALE.C04 in Patients With Head and Neck Cancer | October 30, 2023 | February 2028 |
| NCT06451497 | Recruiting | Phase 1 | Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors | May 22, 2024 | April 2027 |
| NCT06081673 | Recruiting | Phase 2 | Penpulimab Combined With Chemotherapy for Neoadjuvant and Adjuvant Therapy in Patients With Resectable HNSCC | October 30, 2023 | October 30, 2026 |
| NCT06082167 | Recruiting | Phase 2/Phase 3 | Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | November 30, 2023 | March 2028 |
| NCT06087614 | Recruiting | Phase 2 | Dose Escalation Using Hypoxia-adjusted Radiotherapy | April 8, 2024 | April 2028 |
| NCT06088381 | Recruiting | Phase 2 | Selective Adjuvant Therapy for HPV-mediated Oropharynx SCCs Based on Residual Circulating Tumor DNA Levels (SAVAL) | March 7, 2024 | October 18, 2027 |
| NCT06102395 | Recruiting | Phase 3 | Evaluating the Efficacy and Safety of Pembrolizumab Plus Standard Chemotherapy in the Neoadjuvant Treatment of Local Advanced (LA) HNSCC | May 1, 2023 | April 30, 2030 |
| NCT06109207 | Recruiting | Phase 1 | Neoadjuvant Camrelizumab With Dalpiciclib for Resectable Esophageal or Head and Neck Squamous Cell Carcinomas | October 31, 2023 | October 31, 2025 |
| NCT06305247 | Recruiting | Phase 1/Phase 2 | A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours | April 3, 2024 | March 20, 2028 |
| NCT06150664 | Recruiting | Phase 1 | A Phase 1 of CTX-8371 in Patients With Advanced Malignancies | March 19, 2024 | April 2026 |
| NCT06162377 | Recruiting | Phase 4 | Methylnatrexone In Resectable Head and Neck Squamous Cell Carcinoma (MINK). A "Window of Opportunity" Pilot Study. | January 10, 2024 | June 30, 2024 |
| NCT06163534 | Recruiting | A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Head & Neck Squamous Cell Carcinoma (HNSCC) | May 2024 | March 1, 2028 | |
| NCT06170697 | Recruiting | Phase 2 | Advanced First-line Treatment of Short-term Postoperative Progression of Head and Neck Squamous Cell Carcinoma | March 1, 2023 | July 2025 |
| NCT06170710 | Recruiting | Phase 2 | Postoperative CCRT Followed by Immunotherapy in High-Risk LA HNSCC | December 1, 2023 | November 30, 2027 |
| NCT06183268 | Recruiting | N/A | Evaluation of Radiobiological Effects in Skin Toxicities Head and Neck Cancer Patients With PBS Proton Therapy | December 13, 2023 | January 2, 2030 |
| NCT03383094 | Recruiting | Phase 2 | Chemoradiation vs Immunotherapy and Radiation for Head and Neck Cancer | March 15, 2018 | June 2025 |
| NCT03317327 | Recruiting | Phase 1/Phase 2 | REirradiation and Programmed Cell Death Protein 1 (PD-1) Blockade On Recurrent Squamous Cell Head and Neck Tumors | September 9, 2017 | November 2, 2040 |
| NCT06238479 | Recruiting | Phase 1 | A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors | March 5, 2024 | March 4, 2027 |
| NCT03406247 | Recruiting | Phase 2 | Adjuvant Immunotherapy After Salvage Surgery in Head and Neck Squamous Cell Carcinoma | February 12, 2018 | May 2026 |
| NCT06239220 | Recruiting | Phase 2 | PD-L1 t-haNK, N-803 IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC | February 16, 2024 | January 31, 2027 |
| NCT06248996 | Recruiting | Phase 3 | a Multicentre Phase III Study of Risk-based Treatment Intensification With Hyperfractionated Radiotherapy in Head and Neck Cancer Patients | March 4, 2024 | March 4, 2033 |
| NCT03474497 | Recruiting | Phase 1/Phase 2 | UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade | May 20, 2019 | December 2023 |
| NCT03476681 | Recruiting | Phase 1/Phase 2 | Study of NEO-201 in Solid Tumors Expansion Cohorts | January 18, 2019 | October 15, 2026 |
| NCT06273852 | Recruiting | Early Phase 1 | A Study of the Intratumoral Microdose Administration of PBA-0405 in Patients With Solid Tumors | April 29, 2024 | March 2025 |
| NCT03526835 | Recruiting | Phase 1/Phase 2 | A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors | May 2, 2018 | June 2025 |
| NCT03602911 | Recruiting | Phase 2 | A Comparison of NETSPOT Imaging Versus F-FDG-PET in Head and Neck Cancer Patients | February 1, 2019 | July 31, 2019 |
| NCT06366451 | Recruiting | Early Phase 1 | PBI-MST-01 (NCT04541108) Substudy AZN-05: Intratumoral Microdosing of Rilvegostomig, Volrustomig, and Sabestomig in HNSCC | May 22, 2024 | March 2025 |
| NCT04278092 | Recruiting | Phase 2 | Paclitaxel Plus Cetuximab After First-line Checkpoint Inhibitor Failure | February 10, 2020 | July 2024 |
| NCT04291105 | Recruiting | Phase 2 | Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients | April 24, 2020 | March 2025 |
| NCT04369937 | Recruiting | Phase 2 | HPV-16 Vaccination and Pembrolizumab Plus Cisplatin for "Intermediate Risk" HPV-16-associated Head and Neck Squamous Cell Carcinoma | July 6, 2020 | June 30, 2027 |
| NCT04375384 | Recruiting | Phase 2 | Cetuximab After Immunotherapy for the Treatment of Head and Neck Squamous Cell Cancer | July 1, 2020 | January 2025 |
| NCT04429542 | Recruiting | Phase 1 | Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors | June 1, 2020 | June 1, 2025 |
| NCT06378177 | Recruiting | Phase 2 | A Study of LVGN6051 Combination Therapy in Patient With Head and Neck Squamous Cell Carcinoma (HNSCC) | May 17, 2024 | October 31, 2027 |
| NCT04523883 | Recruiting | Phase 2 | Concurrent Immunotherapy With Postoperative Radiotherapy in Intermediate/High Risk HNSCC Patients Unfit for Cisplatin: The IMPORT Study (IMPORT) | August 10, 2020 | August 9, 2024 |
| NCT04564989 | Recruiting | Prospective Observational Study to Validate Circulating HPVDNA and Prognostic Genomic Biomarkers in HPV-associated OPSCC | November 19, 2020 | November 2033 | |
| NCT04567056 | Recruiting | Specific Methylation Profiles in HNSCC | September 16, 2020 | December 20, 2024 | |
| NCT04651634 | Recruiting | Phase 2 | MIT-001 for Prevention of CCRT-Induced OM in HNSCC Patients | June 21, 2021 | December 30, 2024 |
| NCT04675294 | Recruiting | Phase 2 | Evorpacept (ALX148) in Combination With Pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-03) | April 2, 2021 | December 31, 2025 |
| NCT04675333 | Recruiting | Phase 2 | Evorpacept (ALX148) in Combination With Pembrolizumab and Chemotherapy in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-04) | May 10, 2021 | December 31, 2025 |
| NCT04681469 | Recruiting | Phase 2 | Induction and Maintenance Treatment With PARP Inhibitor and Immunotherapy in HPV-negative HNSCC | February 8, 2021 | June 2028 |
| NCT04722523 | Recruiting | Phase 1 | A Study of Cemiplimab With Chemotherapy and Immunotherapy in People With Head and Neck Cancer | January 20, 2021 | June 20, 2026 |
| NCT04802876 | Recruiting | Phase 2 | Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients With PD1-high mRNA Expressing Tumors | April 12, 2021 | March 31, 2027 |
| NCT04807140 | Recruiting | Phase 2 | Neoadjuvant Toripalimab or Toripalimab in Combination With Carboplatin and Nab-paclitaxel in Untreated HNSCC (HNSCC-002) | July 8, 2021 | January 1, 2027 |
| NCT04826679 | Recruiting | Phase 2 | Neoadjuvant Camrelizumab in Combination With Cisplatin and Nab-paclitaxel in Resectable HNSCC | April 1, 2021 | April 1, 2026 |
| NCT04848116 | Recruiting | Phase 2 | Neoadjuvant Targeting of Myeloid Cell Populations in Combination With Nivolumab in Head & Neck Ca | April 24, 2021 | April 2026 |
| NCT04868877 | Recruiting | Phase 1/Phase 2 | A Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR and Anti-c-MET Bispecific Antibody, in Patients With Advanced NSCLC and Other Solid Tumors | April 28, 2021 | April 2025 |
| NCT04938609 | Recruiting | Phase 2 | Neoadjuvant Immunoradiotherapy in Head & Neck Cancer (NIRT 2-HNC) | January 11, 2022 | January 11, 2031 |
| NCT04946968 | Recruiting | Phase 2 | Phase-2 Dacomitinib Study on Patients With EGFR-Driven Advanced Solid Tumours With Low EGFR-AS1 IncRNA Expr or Other Novel Emerging Biomarkers | August 24, 2021 | June 2028 |
| NCT04977453 | Recruiting | Phase 1/Phase 2 | GI-101 as a Single Agent or in Combination With Pembrolizumab, Lenvatinib or Local Radiotherapy in Advanced Solid Tumors | August 2, 2021 | October 2026 |
| NCT04999800 | Recruiting | Phase 2 | Study of Pembrolizumab Combined With Anlotinib in the First Line Therapy for R/M HNSCC With CPS≥1 | July 18, 2021 | June 30, 2024 |
| NCT05005403 | Recruiting | Phase 1 | Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Budigalimab | November 1, 2021 | May 4, 2026 |
| NCT05031910 | Recruiting | N/A | Virtual Reality 3D-Surgery Modeling to Enhance Head and Neck Cancer Surgery Quality | February 4, 2022 | June 2027 |
| NCT05044117 | Recruiting | Phase 3 | Single-agent Capecitabine as Metronomic Chemotherapy in LAHNSCC (CMHN) | October 18, 2021 | October 2026 |
| NCT05044897 | Recruiting | Phase 2 | A Clinical Study to Evaluate the Efficacy and Safety of SI-B001 in the Treatment of Recurrent and Metastatic HNSCC | October 20, 2021 | April 2024 |
| NCT05047094 | Recruiting | N/A | A Safety and Efficacy Study for Combinational Treatment of DaRT and Check Point Inhibitor for Recurrent Unresectable or mHNSCC | November 2, 2021 | June 2027 |
| NCT05054439 | Recruiting | Phase 2 | A Clinical Study of SI-B001 in Combination With Paclitaxel in the Treatment of Recurrent and Metastatic HNSCC | December 22, 2021 | June 2024 |
| NCT05075122 | Recruiting | Phase 2 | Tolerability and Efficacy of UV1 Vaccine in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Planned for First-line Treatment With Pembrolizumab | August 2, 2021 | February 2025 |
| NCT05077709 | Recruiting | Phase 2 | IO102-IO103 in Combination With Pembrolizumab as First-line Treatment for Patients With Metastatic NSCLC, SCCHN, or mUBC | February 14, 2022 | November 30, 2024 |
| NCT05094804 | Recruiting | Phase 1/Phase 2 | A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents | September 9, 2021 | August 15, 2024 |
| NCT05098132 | Recruiting | Phase 1 | Phase 1a/1b Study of STK-012 Monotherapy and in Combination With Pembrolizumab in Patients With Solid Tumors | January 25, 2022 | October 2025 |
| NCT05107674 | Recruiting | Phase 1 | A Study of NX-1607 in Adults With Advanced Malignancies | September 29, 2021 | February 28, 2026 |
| NCT05122507 | Recruiting | Liquid Biopsy of Head and Neck Cancer Patients in Blood and Saliva | May 8, 2017 | April 2023 | |
| NCT05136196 | Recruiting | Phase 2 | BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study | December 6, 2022 | September 1, 2024 |
| NCT05143268 | Recruiting | Acupuncture for Dysphagia in Head and Neck Squamous Cell Carcinoma | June 3, 2021 | October 30, 2023 | |
| NCT05172258 | Recruiting | Phase 2 | Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck | July 26, 2022 | June 30, 2025 |
| NCT05176483 | Recruiting | Phase 1 | Study of XL092 in Combination With Immuno-Oncology Agents in Subjects With Solid Tumors | December 14, 2021 | May 2026 |
| NCT05183048 | Recruiting | Early Phase 1 | Comparison of 89Zr Panitumumab and (18)F-Fluorodeoxyglucose to Identify Head and Neck Squamous Cell Carcinoma | December 31, 2024 | March 31, 2026 |
| NCT05213884 | Recruiting | Phase 2 | The Efficacy of Induction and Adjuvant Camrelizumab Combined With Chemoradiation for LA-HNSCC | January 1, 2022 | January 1, 2027 |
| NCT05217212 | Recruiting | Do Markers of Systemic Inflammatory Response and Tumor Metabolism Indicate Radioresistance in Head and Neck Cancer? | January 1, 2020 | December 2025 | |
| NCT05222932 | Recruiting | Phase 1 | Oncolytic Adenovirus TILT-123 and Avelumab for Treatment of Solid Tumors Refractory to or Progressing After Anti-PD(L)1 | March 8, 2023 | December 2026 |
| NCT05229614 | Recruiting | Phase 2 | Immunotherapy and Carbon Ion Radiotherapy In Solid Cancers With Stable Disease | July 26, 2022 | August 2026 |
| NCT05238883 | Recruiting | Phase 1 | A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors | March 10, 2022 | December 2026 |
| NCT05239143 | Recruiting | Phase 1 | P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid Tumors | February 15, 2022 | April 2039 |
| NCT05272696 | Recruiting | Phase 2 | Pembrolizumab and Induction Chemotherapy in Locally Advanced HNSCC | March 1, 2022 | January 1, 2025 |
| NCT05280457 | Recruiting | Phase 2 | HPV 16-positive and/or HPV 18-positive Recurrent and/or For Patients With Metastatic Head and Neck Cancer to Evaluate GX-188E DNA Vaccination, GX-I7 and Nivolumab Combination Therapy | April 15, 2022 | March 2026 |
| NCT05286060 | Recruiting | Phase 2 | Trial of the Combination of GX-188E Vaccination, GX-I7 and Pembrolizumab in Patients With Advanced, Resectable HPV Type 16 and/or 18 Positive Head and Neck Cancer | March 1, 2022 | December 2025 |
| NCT05286294 | Recruiting | Phase 2 | Microbiota Transplant to Cancer Patients Who Have Failed Immunotherapy Using Faeces From Clinical Responders | June 28, 2022 | December 31, 2034 |
| NCT04254107 | Terminated | Phase 1 | A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer | May 29, 2020 | December 1, 2023 |
| NCT04032704 | Terminated | Phase 2 | A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors | October 9, 2019 | November 28, 2023 |
| NCT01824823 | Terminated | Phase 2 | Afatinib After Chemoradiation and Surgery in Treating Patients With Stage III-IV Squamous Cell Carcinoma of the Head and Neck at High-Risk of Recurrence | June 30, 2014 | December 2020 |
| NCT02488629 | Terminated | Phase 2 | Study of SCB01A in Patient With Head and Neck Cancer | September 2015 | December 2017 |
| NCT04762225 | Terminated | Phase 1 | RPTR-168 in Patients With Human Papillomavirus Strain 16 (HPV-16) E6/E7 Positive Tumors and Melanoma | May 10, 2021 | October 11, 2022 |
| NCT01975688 | Terminated | Phase 1 | A Pharmacokinetic Study of Single Doses of Sativex in Treatment-induced Mucositis | February 2014 | June 2015 |
| NCT04099277 | Terminated | Phase 1 | A Study of LY3435151 in Participants With Solid Tumors | October 28, 2019 | March 5, 2020 |
| NCT02706691 | Terminated | Phase 2 | BGJ398 in Treating Patients With FGFR Positive Recurrent Head and Neck Cancer | June 1, 2018 | February 11, 2019 |
| NCT02524275 | Terminated | Phase 2 | Docetaxel and Capecitabine With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck | March 30, 2015 | October 28, 2021 |
| NCT03655444 | Terminated | Phase 1/Phase 2 | Abemaciclib + Nivolumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed or Recurred Within Six Months After Platinum-based Chemotherapy | May 29, 2019 | August 24, 2020 |
| NCT04244552 | Terminated | Phase 1 | A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies | February 11, 2020 | November 1, 2023 |
| NCT02892201 | Terminated | Phase 2 | Pembrolizumab in HNSCC With Residual Disease After Radiation | September 8, 2016 | March 2020 |
| NCT02365662 | Terminated | Phase 1 | A Study Evaluating Safety and Pharmacokinetics of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor | January 9, 2015 | March 15, 2018 |
| NCT00805012 | Terminated | Phase 2 | Docetaxel and S-1 in Head and Neck Squamous Cell Carcinoma (HNSCC) | December 2008 | July 2011 |
| NCT05363605 | Terminated | Phase 1/Phase 2 | A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours | April 20, 2022 | September 8, 2023 |
| NCT03094169 | Terminated | Phase 1/Phase 2 | AVID100 in Advanced Epithelial Carcinomas | February 1, 2017 | January 30, 2021 |
| NCT03463161 | Terminated | Phase 2 | Epacadostat and Pembrolizumab in Patients With Head and Neck Cancer That Have Failed Prior Immunotherapy | March 23, 2018 | December 4, 2018 |
| NCT02345330 | Terminated | Phase 2 | Trial of pIL-12 Electroporation in Squamous Cell Carcinoma of the Head and Neck (IL12HNSCC) | May 21, 2015 | November 14, 2016 |
| NCT04193293 | Terminated | Phase 1/Phase 2 | A Study of Duvelisib in Combination With Pembrolizumab in Head and Neck Cancer | June 1, 2020 | December 10, 2020 |
| NCT03957096 | Terminated | Phase 1 | A Safety Study of SGN-CD47M in Patients With Solid Tumors | July 17, 2019 | September 14, 2020 |
| NCT03435640 | Terminated | Phase 1/Phase 2 | REVEAL Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients With Locally Advanced / Metastatic Solid Tumor Malignancies | March 15, 2018 | May 9, 2022 |
| NCT04000529 | Terminated | Phase 1 | Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies | July 30, 2019 | January 15, 2024 |
| NCT04624113 | Terminated | Phase 1 | Tazemetostat and Pembrolizumab in Patients With Pembrolizumab- or Nivolumab-Resistant, Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma | April 14, 2021 | February 17, 2024 |
| NCT04634825 | Terminated | Phase 2 | Enoblituzumab Plus Retifanlimab or Tebotelimab in Head and Neck Cancer | March 17, 2021 | July 29, 2022 |
| NCT01852292 | Terminated | Phase 2 | Study of Efficacy and Safety of Buparlisib (BKM120) Plus Paclitaxel Versus Placebo Plus Paclitaxel in Recurrent or Metastatic Head and Neck Cancer Previously Pre-treated With a Platinum Therapy | October 1, 2013 | March 30, 2017 |
| NCT03720158 | Terminated | N/A | Enteral Omega 3 During Radiotherapy to Improve the Quality of Life and Functionality of Head and Neck Cancer Patients | October 10, 2018 | July 31, 2021 |
| NCT02901483 | Terminated | Phase 1/Phase 2 | A Study of PEP503 With Radiotherapy in Combination With Concurrent Chemotherapy for Patients With Head and Neck Cancer | October 11, 2016 | August 17, 2020 |
| NCT05219578 | Terminated | Phase 1/Phase 2 | RTX-224 Monotherapy in Patients With Solid Tumors | January 12, 2022 | November 30, 2022 |
| NCT04442126 | Terminated | Phase 1/Phase 2 | A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors | August 19, 2020 | February 6, 2024 |
| NCT02582008 | Terminated | Early Phase 1 | Bupropion Hydrochloride or Patient's Choice for Smoking Cessation in Patients With Squamous Cell Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy | January 2016 | September 6, 2019 |
| NCT04110249 | Terminated | N/A | Photoacoustic Imaging for Measuring Tumors and Normal Tissue in Patients With Head and Neck Cancer | September 6, 2019 | December 29, 2022 |
| NCT02495896 | Terminated | Phase 1 | Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors | September 3, 2015 | May 29, 2019 |
| NCT04060342 | Terminated | Phase 1 | GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma | August 13, 2019 | April 11, 2022 |
| NCT05299203 | Unknown status | Phase 1 | BH4 in the Prevention and Treatment of Radiation-induced Skin Reactions for Head and Neck Squamous Cell Carcinoma (Including Nasopharyngeal Carcinoma) | May 2022 | May 2023 |
| NCT02004639 | Unknown status | N/A | Trismus Prevention, Diagnosis and Management: Radiotherapy Planning, Early Detection, and Physical Therapy Intervention | March 2013 | |
| NCT02661152 | Unknown status | Phase 3 | DAHANCA 30: A Randomized Non-inferiority Trial of Hypoxia-profile Guided Hypoxic Modification of Radiotherapy of HNSCC. | September 2016 | December 2023 |
| NCT02639858 | Unknown status | Phase 2 | Study to Evaluate the Efficacy and Safety of Docetaxel Polymeric Micelle (PM) in Recurrent or Metastatic HNSCC | October 2015 | September 2020 |
| NCT02915432 | Unknown status | Phase 1/Phase 2 | The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCC | December 2016 | April 30, 2022 |
| NCT03134846 | Unknown status | Phase 1/Phase 2 | Image Guided Surgery for Margin Assessment of Head and Neck Cancer Using Cetuximab-IRDye800CW cONjugate | December 16, 2017 | June 2022 |
| NCT04399785 | Unknown status | Phase 2 | Phase II Study for Combination of Camrelizumab and SBRT in the First-line Treatment for R/M HNSCC | June 1, 2020 | June 1, 2022 |
| NCT05267353 | Unknown status | N/A | Develop and Test the 'Multi-Faced Continuous Exercise Program' in Operable Head and Neck Cancer Patients | January 22, 2013 | December 31, 2022 |
| NCT04440917 | Unknown status | Phase 2 | Camrelizumab Combined With Apatinib Mesylate for Head and Neck Squamous Cell Carcinoma | June 3, 2020 | December 2023 |
| NCT00634777 | Unknown status | N/A | Assessment of Regional Response With PET-FDG in Advanced Head and Neck Squamous Cell Carcinoma | January 2007 | January 2012 |
| NCT02507154 | Unknown status | Phase 1/Phase 2 | Reactivating NK Cells in Treating Refractory Head and Neck Cancer | July 2015 | August 2019 |
| NCT05289336 | Unknown status | Phase 2 | DAHANCA 27 Transoral Laser Microsurgery for T1a Glottic Cancer | September 1, 2012 | May 1, 2022 |
| NCT05291663 | Unknown status | Effect of Accelerated RTH in Squamous Cell Carcinoma in Head and Neck | March 20, 2022 | December 20, 2023 | |
| NCT05294900 | Unknown status | Phase 2 | Trial of Neoadjuvant Therapy With Paclitaxel and Carboplatin in Operable Locally Advanced Head and Neck Cancer Patients | May 2022 | June 2024 |
| NCT04045496 | Unknown status | Phase 1 | A First-in-Human, Phase 1 Study of JAB-3312 in Adult Patients With Advanced Solid Tumors | September 26, 2019 | March 2024 |
| NCT04721223 | Unknown status | Phase 1/Phase 2 | JAB-3068 Activity in Adult Patients With Advanced Solid Tumors | April 26, 2021 | October 28, 2022 |
| NCT04164238 | Unknown status | Phase 2 | Neoadjuvant Anti-PD-1 Antibody (Toripalimab) or Combined With Chemotherapy in HNSCC Patients | November 7, 2019 | November 7, 2021 |
| NCT04740996 | Unknown status | Study of Pembrolizumab in the First Line Therapy for R/M HNSCC in China | February 4, 2021 | February 2024 | |
| NCT04803331 | Unknown status | N/A | SPIO-enhanced MRI in Oral Cancer for Sentinel Lymph Node Identification | July 27, 2021 | July 1, 2023 |
| NCT03926468 | Unknown status | Liquid Biopsy in Head and Neck Cancer | August 1, 2019 | December 31, 2022 | |
| NCT03196843 | Unknown status | Phase 4 | Radiotherapy Combine With Raltitrexed Versus Radiotherapy Alone in Older Patients With HNSCC. | September 1, 2017 | August 2023 |
| NCT04843098 | Unknown status | Phase 1/Phase 2 | Study of TL117 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | April 2021 | January 2024 |
| NCT02881918 | Unknown status | Anti-tumor Specific Immune Response in Head and Neck Cancers | March 14, 2017 | March 2021 | |
| NCT04146402 | Unknown status | Phase 3 | SCT-I10A Plus Standard Chemotherapy in First-line Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma | December 31, 2019 | July 30, 2022 |
| NCT03424291 | Unknown status | Phase 2 | A Retrospective Clinical Study of Apatinib in Combination With Radiotherapy / Chemotherapy Second-line and Above in the Treatment of Recurrent / Metastatic Head and Neck Squamous Cell Carcinoma | July 5, 2017 | July 2019 |
| NCT05008796 | Unknown status | PD-L1 Expression on CTCs in HNSCC Patients Underwent Curative CCRT | August 1, 2021 | July 31, 2022 | |
| NCT04146181 | Unknown status | Phase 2 | Safety and Efficacy of SCT-I10A in Head and Neck Squamous Cell Carcinoma | October 31, 2019 | September 30, 2021 |
| NCT03896412 | Unknown status | N/A | Detection of Circulating Tumor DNA in p16- Locally Advanced Head Neck Squamous Cell Carcinoma | January 21, 2019 | May 19, 2022 |
| NCT03096184 | Unknown status | Phase 2 | A Study of Apatinib Plus Tegafur Gimeracil Oteracil in Recurrent/Metastatic Head and Neck Cancers | December 23, 2016 | May 1, 2019 |
| NCT03874741 | Unknown status | Phase 2 | SCT200 Plus Platinum-based Chemotherapy in Head and Neck Squamous Cell Carcinoma | May 21, 2019 | July 1, 2021 |
| NCT05065086 | Unknown status | Single Modality Trans Oral Robotic Surgery for Primary Oropharyngeal Cancer: Exploring the Impact of Surgical Margins on Local Disease Recurrence | September 2, 2021 | July 30, 2022 | |
| NCT03450967 | Unknown status | Phase 2 | Durvalumab Plus Tremelimumab Combined With Proton Therapy for HNSCC | April 11, 2018 | March 2022 |
| NCT05117138 | Unknown status | Phase 1/Phase 2 | Safety and Efficacy of Chimeric Antigen Receptor T Lymphocytes for Patients With Intermediate and Advanced Tumors | January 1, 2022 | March 1, 2024 |
| NCT03578406 | Unknown status | Phase 1 | HPV-E6-Specific Anti-PD1 TCR-T Cells in the Treatment of HPV-Positive NHSCC or Cervical Cancer | September 1, 2018 | August 30, 2021 |
| NCT02126189 | Unknown status | The Princess Alexandra Hospital and the QIMR Berghofer Medical Research Institute Head and Neck Cancer Study | November 2013 | November 2016 | |
| NCT03053661 | Unknown status | Immune Response Evaluation to Curative Conventional Therapy | August 2013 | August 2020 | |
| NCT01377298 | Unknown status | Phase 2 | Pazopanib in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | June 2011 | May 2014 |
| NCT05202275 | Unknown status | Phase 2 | The Optimization of Antiemetic Regimen for C-RINV in LA-HNSCCs | December 1, 2020 | September 2023 |
| NCT03744208 | Unknown status | Phase 2 | SCT200 Injection in Patients With Head and Neck Squamous Cell Carcinoma | December 30, 2018 | May 28, 2020 |
| NCT04831450 | Withdrawn | Phase 2 | Phase 2 Trial of Maintenance Cemiplimab for Head and Neck Squamous Cell Carcinoma (HNSCC) | July 2022 | July 15, 2022 |
| NCT04003025 | Withdrawn | Body Composition and Prognosis in Head and Neck Squamous Cell Carcinoma (HNSCC) | July 30, 2019 | March 1, 2021 | |
| NCT02567396 | Withdrawn | Phase 1 | Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be Removed by Surgery and Liver or Kidney Dysfunction | June 2016 | |
| NCT02143622 | Withdrawn | Phase 1/Phase 2 | Study of Efficacy and Safety of LJM716 and Cetuximab in Head and Neck Squamous Cell Carcinoma Patients | March 2015 | August 2018 |
| NCT03169764 | Withdrawn | Phase 1/Phase 2 | QUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy in Subjects With HNSCC Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy | December 2017 | March 2019 |
| NCT05220748 | Withdrawn | Phase 1 | RM-1995 Photoimmunotherapy, as Monotherapy or Combined With Pembrolizumab, in Patients With Advanced CuSCC and HNSCC | March 24, 2022 | January 30, 2023 |
| NCT05412875 | Withdrawn | N/A | Pilot Trial of E Cigarettes in Pts Diagnosed With Cancer of the Head, Neck, and Lung | January 1, 2024 | January 31, 2024 |
| NCT05472506 | Withdrawn | Phase 1 | Oral AHR Antagonist in Combination With Nivolumab in Patients With PD-1 Resistant Metastatic or Recurrent Head and Neck Cancer | March 2023 | April 2023 |
| NCT02593929 | Withdrawn | Early Phase 1 | Pharmacodynamic Effects and Predictive Biomarkers With Ruxolitinib in Operable Head and Neck Cancer | January 2017 | |
| NCT04987996 | Withdrawn | Phase 2 | GR-MD-02 + Pembrolizumab Versus Pembrolizumab Monotherapy in Melanoma and Squamous Cell Head and Neck Cancer Patients | July 1, 2023 | July 1, 2031 |
| NCT05099952 | Withdrawn | N/A | Sleep and Circadian Rhythm Study in Head and Neck Cancer Patients | December 15, 2021 | December 15, 2026 |
| NCT05393635 | Withdrawn | Phase 1 | ITIL-168 in Advanced Solid Tumors | August 2022 | December 8, 2022 |
| NCT04464967 | Withdrawn | Phase 1/Phase 2 | Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers | March 2021 | February 2023 |
| NCT04093115 | Withdrawn | Phase 2 | Study of CX1106 in Patients With Advanced Head and Neck Squamous Cell Carcinoma | December 9, 2019 | March 31, 2020 |
- Disase is a (Disease Ontology)
- DOID:1542
- Cross Reference ID (Disease Ontology)
- GARD:8503
- Cross Reference ID (Disease Ontology)
- MESH:D000077195
- Cross Reference ID (Disease Ontology)
- MIM:275355
- Cross Reference ID (Disease Ontology)
- NCI:C34447
- Cross Reference ID (Disease Ontology)
- SNOMEDCT_US_2023_03_01:716659002
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C1168401
- Exact Synonym (Disease Ontology)
- carcinoma of the head and neck
- Exact Synonym (Disease Ontology)
- squamous cell carcinoma of the head and neck
- Exact Synonym (Disease Ontology)
- squamous cell carcinomas of head and neck